Pandion Therapeutics

pipeline pipes RD research

Biotech

Merck axes main asset from $1.9B Pandion buyout

MK-6194 was being studied in a pair of phase 2 trials for lupus and vitiligo. Merck picked up the asset from Pandion in a $1.9 billion acquisition.

Gabrielle Masson Jul 29, 2025 2:42pm

insider trading stock shares SEC

Insider trading off Merck-Pandion deal was family affair: SEC

Nov 11, 2022 10:45am

illegal trading stock market

SEC charges 2 with insider trading over Merck-Pandion deal

Jul 26, 2022 5:30am

A sheet of paper reading venture capital

Seismic, padded by ex-Pandion C-suite, unveils with $101M

Feb 9, 2022 7:00am

Versant nets $950M to build its next class of biotech startups

Apr 21, 2021 8:55am

Merck

How Pandion went from a $65M Merck offer to a $1.9B done deal

Mar 5, 2021 9:09am